antiviral news

Press Releases in the global landscape
Apr 2, 2025

Nirmatrelvir/Ritonavir Reduces Post-Acute Mortality in Immunocompromised COVID-19 Patients

In a new study, Marc Ka-Chun Chong, PhD discusses the antiviral's impact on survival and hospitalization outcomes.
Read More »
Apr 2, 2025

Xocova’s US Rolling Submission Starts for COVID Post-Exposure Prophylaxis

Shionogi said on April 1 that it has initiated the rolling submission of a new drug application in the US for its oral antiviral Xocova (ensitrelvir) for an additional indication of post-exposure prophylaxis for COVID-19.
Read More »
Apr 2, 2025

A Small-Molecule SARS-CoV-2 Inhibitor Targeting the Membrane Protein

[Nature] Investigators described the identification of JNJ-9676, a small-molecule inhibitor targeting the coronavirus M protein.
Read More »
Apr 2, 2025

New COVID-19 drug shows greater promise against resistant viral strains

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.
Read More »
Mar 28, 2025

Ensitrelvir reduces household spread of SARS-CoV-2, study shows

Ensitrelvir reduced transmission of SARS-CoV-2 by 67% when given to uninfected household contacts of a person with COVID-19 within 3 days of that person developing symptoms, researchers reported.
Read More »
Mar 28, 2025

Xocova Filed for Post-Exposure Prophylaxis for COVID-19 in Japan

Shionogi said on March 27 that it has filed its oral antiviral Xocova (ensitrelvir) for an additional indication of post-exposure prophylaxis for COVID-19 in Japan.
Read More »